Missed Opportunities to Prevent Mother-to-Child-Transmission in sub-Saharan Africa: Systematic Review and Meta-Analysis

Celina WETTSTEIN1, Catrina MUGGLIN1, Matthias EGGER1,2, Nello BLASER1, Luisa SALAZAR1, Janne ESTILL1, Nicole BENDER1, Mary-Ann DAVIES2, Gilles WANDELER1,3,* , and Olivia KEISER1,*

1Division of International and Environmental Health, Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland 2School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa 3Infectious Diseases Clinic, Bern University Hospital, Bern, Switzerland

Abstract

Objectives—To determine magnitude and reasons of loss to programme and poor antiretroviral prophylaxis coverage in prevention of mother-to-child transmission (PMTCT) programmes in sub-Saharan Africa.

Design—Systematic review and meta-analysis.

Methods—We searched PubMed and Embase databases for PMTCT studies in sub-Saharan Africa published between January 2002 and March 2012. Outcomes were the percentage of pregnant women (i) tested for HIV, (ii) initiating antiretroviral prophylaxis, (iii) having a CD4 cell count measured, and (iv) initiating antiretroviral combination therapy (cART) if eligible. In children outcomes were (v) early infant diagnosis for HIV, and (vi) cART initiation. We combined data using random-effects meta-analysis and identified predictors of uptake of interventions.

Results—Forty-four studies from 15 countries including 75,172 HIV-infected pregnant women were analyzed. HIV-testing uptake at antenatal care services was 94% (95% confidence intervals [CI] 92-95%) for opt-out and 58% (95% CI 40-75%) for opt-in testing. Coverage with any antiretroviral prophylaxis was 70% (95% CI 64-76%) and 62% (95% CI 50-73%) of pregnant women eligible for cART received treatment. Sixty-four percent (95% CI 48-81%) of HIV exposed infants had early diagnosis performed and 55% (95% CI 36-74%) were tested between 12 and 18 months. Uptake of PMTCT interventions was improved if cART was provided at the antenatal clinic and if the male partner was involved.

Conclusions—In sub-Saharan Africa, uptake of PMTCT interventions and early infant diagnosis is unsatisfactory. An integrated family-centered approach seems to improve retention.

Correspondence to: Olivia Keiser and Celina Wettstein, Institute of Social and Preventive Medicine (ISPM), University of Bern, Finkenhubelweg 11, CH-3012, Bern, Switzerland. Tel.: +41 31 631 35 15; Fax: +41 31 631 35 20; ails.okeiser@ispm.unibe.ch, cwettstein@ispm.unibe.ch.

*equal contribution

Conflicts of Interest
The authors have no conflicts of interest to declare.

Contributions: Analyzed the data: CW, CM, OK. Wrote the paper: CW, GW, OK. Conceived and designed the systematic review: CW, ME, OK. Performed data extraction: CW, CM, NB, LS, JE, NB, GW, OK. Revised the paper: ME, MD.
Keywords

pre-ART; linkage to care; mortality; loss to follow-up; PMTCT; early infant diagnosis; prophylaxis

Introduction

In 2009 approximately 130,000 children were newly infected with HIV in sub-Saharan Africa, over 90% of them by vertical transmission [1, 2]. If HIV infected infants are left undiagnosed and untreated, about half of them die before the age of two [2]. Mother-to-child transmission, which occurs in 20 to 45% of HIV-infected pregnant women without antiretroviral prophylaxis, can be lowered to \( \leq 5\% \) with adequate interventions [2]. Early infant diagnosis (EID) and treatment after delivery dramatically reduce infant mortality [3]. However, loss to follow-up of mothers and their infants from prevention of mother-to-child transmission (PMTCT) programs limits the impact of these interventions.

PMTCT interventions can be seen as a series of consecutive steps (Figure 1). When pregnant women first present at an antenatal care unit, they are tested for HIV. If positive, they are counseled for PMTCT and provided with antiretroviral medication. They are also assessed for eligibility for lifelong antiretroviral combination therapy (cART) and if they are eligible, therapy is initiated. With the option B+ approach for PMTCT this last step is unnecessary as all pregnant women start cART [4]. EID of HIV by polymerase chain reaction (PCR) is performed on infants if their mothers return with them for postnatal follow-up, preferably at around six weeks after delivery. In infants who test negative at EID or if no EID is available, the final HIV status is determined after weaning. Finally, cART is initiated in HIV-infected infants.

At each step of the PMTCT cascade, pregnant women and their infants may be lost to follow-up and not benefit from important health-care interventions. The magnitude and reasons for program attrition in sub-Saharan Africa remain poorly understood. We performed a systematic review and meta-analysis to evaluate the uptake of HIV testing and antiretroviral treatment in pregnant women and their children.

Methods

Data sources

We searched Pubmed and Embase databases on March 5\(^{th}\) 2012, limiting the search to publications in the English language and studies published since 2002 (i.e. when the scale-up of ART programs in sub-Saharan Africa began) [5]. We used free text words as well as Medical Subjects Headings (MeSH) in Pubmed and Emtree-terms in Embase. We combined the following search terms and their variations: HIV, prevention of mother-to-child-transmission, infection of newborn, pregnancy, prenatal care, postnatal care, antiretroviral agents, eligibility, referral process and loss to follow-up. We examined the references of all included studies. Further details on the search strategy are given in the webappendix.

Study selection

We included all studies on pregnant women (with either unknown or positive HIV status) and their HIV-exposed infants who attended PMTCT programs in sub-Saharan Africa. We selected studies that reported the number of participants who were given access to at least one of the following interventions: initiation of antiretroviral prophylaxis for HIV positive pregnant women; assessment and initiation of lifelong cART; or HIV testing in infants. We
excluded qualitative studies, randomized controlled trials, modeling studies, studies where uptake of interventions was assessed by interview, and cost-effectiveness studies. Abstracts were screened according to a list of inclusion and exclusion criteria. Two reviewers independently assessed the eligibility of articles. Discrepancies were resolved by consensus.

Data extraction

Data extraction was performed in duplicate by eight reviewers using a standardized extraction sheet. The following data were extracted: characteristics of programs (setting, location, country) and participants (age, gestational age at first antenatal care visit), eligibility criteria for cART initiation and the number of participants completing the following steps: (i) HIV-testing of pregnant women; (ii) initiation of antiretroviral prophylaxis for mothers; (iii) CD4 cell count testing; (iv) initiation of cART in eligible women; (v) HIV diagnosis of the exposed infants around 6 weeks by PCR and between 12 and 18 months by PCR or antibody test; and (vi) cART initiation in infected infants (Figure 1). Eligibility was defined according to the programme threshold in use at the time of the study. We also extracted predictors of successful uptake of each step and recorded positive or negative associations with the outcomes studied. Discrepancies were resolved by consensus.

Statistical analysis

We assessed the percentage of participants who completed each of the steps, and estimated the underlying mean percentage by combining studies in random-effect meta-analysis. Calculations were done on the logit scale with results back-transformed to percentages. Results were heterogeneous with $I^2$ values consistently above 90% and $p$ values from tests of heterogeneity <0.001. We therefore calculated approximate prediction intervals (PrI) based on the whole random-effects distribution as well as traditional 95% confidence intervals (CI) around the mean of the distribution. PrI predict the likely underlying mean percentages in new studies and are the most sensible way to summarize the results of heterogeneous studies [6]. The percentage of women tested for HIV in programs with opt-in and opt-out strategies were compared in a random-effects meta-regression model. To calculate overall PMTCT-coverage, all regimens (single dose nevirapine at birth, dual and triple antiretroviral prophylaxis, as well as cART prescribed for life) were considered. For the meta-analysis on testing between 12 and 18 months postpartum, only infants from programs without PCR-testing or with negative early PCR test result were included. Data were analyzed using STATA version 12 (StataCorp, Texas, USA).

Results

Study and patient characteristics

We identified 146 potentially eligible full text articles out of 2,370 identified studies based on titles and abstracts. Fifty-six publications met our inclusion criteria but a further 12 articles were excluded because they reported on the same populations and time periods as other articles. A total of 44 studies including 75,172 HIV positive women were included. Details on the selection process are provided in the webappendix (Figure S1). The studies originated from 15 countries in sub-Saharan Africa (webappendix Figure S2). The number of patients in each publication ranged from 22 to 14,815 (Table 1) [7, 8]. Eight studies reported on the gestational age at presentation to antenatal care [9-16] the majority of women were in the late second or third trimester (webappendix Table S1). Many studies provided information on HIV testing (N=27) or antiretroviral prophylaxis without cART-eligibility assessment (N=23). Eligibility for cART was assessed in 14 programs, and 12 studies reported on cART-initiation in eligible women. Thirteen studies reported on uptake
of EID, eight on HIV testing between 12 and 18 months postpartum and one study reported on treatment initiation in infected infants (Figure 1).

HIV testing of pregnant women

In sites where provider initiated (opt-out) testing was performed, the combined estimate of women tested for HIV, based on nine studies, was 93.7%, with 95% CI of 92.4-95.0% and only slightly wider PrI of 88.7-98.6%. The combined estimate for opt-in testing, based on seven studies, was 57.6%, with a 95% CI of 40.0-75.1% and a PrI of 0-100% (Figure 2). The results from the two testing strategies were clearly different (p <0.001 from meta-regression). Predictors of successful HIV testing were reported in six publications [10, 17-21] and included cART provision at the antenatal clinic [21] and being accompanied by a male partner [20] (webappendix Table S2).

Antiretroviral prophylaxis for PMTCT

The combined estimate of the percentage of HIV positive women receiving any type of prophylaxis, based on 34 studies, was 70.3%, with 95% CI and PrI of 64.3-76.3% and 33.7%-100.0%, respectively (Figure 3, webappendix Figure S3). In 19 of these programs, the only PMTCT intervention consisted of sdNVP at birth. In three studies, women initiated lifelong cART if eligible and received sdNVP otherwise. Dual or triple ART prophylaxis was available in nine studies, with an estimate of mean coverage of 58.6% and 95% CI and PrI of 41.0-76.2% and 0-100%, respectively (Figure 3, webappendix Figure S4). In six of these nine studies, some women received sdNVP even though dual or triple ART was available. The reason for this was that the women received sdNVP at their first visit but never returned for an assessment of ART eligibility [15, 22]. In three of the 34 studies the antiretroviral regimen was not specified. Information on predictors of sdNVP uptake was available in six studies [10, 13, 17, 19, 20, 23]. Uptake was better when the male partner was involved [20] and when women delivered at the health care facility [19] (webappendix Table S2).

Eligibility assessment and cART initiation

Ten studies reported on uptake of assessments of cART eligibility based on CD4 cell counts and subsequent cART initiation. In these studies, a CD4 cell count was determined in 67.6% of HIV-infected pregnant women (95% CI 37.5-97.8%; PrI 0-100%). An estimated 22.3% of women who had a CD4 count were eligible for cART (95% CI 17.2-27.4%; PrI 3.0-41.6%) and an estimated 61.1% of these women initiated treatment (95% CI 47.7-74.5%; PrI 10.4-100%) (Figure 3, webappendix Figure S5). Results were similar when including all studies with information on any one of these steps (webappendix Figure S6): the estimated percentage of HIV positive women with a CD4 cell count, based on 14 studies, was 68.1% (95% CI 44.6-91.7%; PrI 0-100%). Among these 22.6% of women were eligible for cART (95% CI 17.8-27.5%; PrI 3.9-41.4%, based on 11 studies) and 61.5% of eligible women initiated cART (95% CI 49.8-73.2%; PrI 16-2-100, 11 studies.). Six studies assessed whether women with CD4 cell measurements returned to collect the results: an estimated 72.6% (95% CI 62.5-82.7%; PrI 35.5-100%) returned to the clinic.

Four studies reported on predictors for having a CD4 cell count recorded [8, 13, 18, 24]. A CD4 count was more likely to be recorded if the measurement was ordered on the same day as testing for HIV was done [8], if the result was available rapidly [8], if the test was done in urban areas [8], if the women was employed [18], or if the gestational age at the first visit was below 20 weeks [18]. Five studies reported on predictors for cART initiation in eligible women [8, 13, 18, 21, 24, 25]. Women were more likely to start cART if it was provided at the antenatal clinic [8, 24], if they were older [25], had more children [25], or presented earlier in pregnancy [21] (webappendix Table S2).
Linkage between PMTCT services, infant HIV diagnosis and cART initiation

The mean percentage of infants tested for HIV by PCR around 6 weeks based on 12 studies was 64.4% with 95% CI and PrI of 47.5-81.2% and 0%-100%, respectively (Figure 4, webappendix Table S3). Predictors for early infant diagnosis were reported in three studies [26-28]. These showed positive associations between uptake of testing and proximity to the clinic [26], large family size [26], early HIV diagnosis of the mother [27], or having received antiretroviral prophylaxis for PMTCT [27] (webappendix Table S2). The combined estimate of the percentage of infants tested between 12 and 18 months postpartum based on 7 studies was 55.2% with 95% CI 36.4-74.1% and PrI 0.0-100.0% (Figure 4, webappendix Table S3). Only one study followed the HIV infected children until cART initiation: 29.5% of infected infants could be traced to an ART clinic and of these about half initiated cART [29].

Discussion

Our meta-analysis included over 75,000 pregnant women from 15 countries in sub-Saharan Africa who had been enrolled in 44 studies of one or several steps of the PMTCT cascade. The results of the different studies were heterogeneous, and in some instances very heterogeneous, with maximally wide prediction intervals. Provider initiated (opt-out) HIV testing of pregnant women resulted in much higher coverage than patient-initiated (opt-in) testing, with an estimated 94% of women being tested with the first approach compared to 58% with the second. The uptake of antiretroviral prophylaxis for mothers was unsatisfactory, and the percentage of cART eligible patients who received the recommended treatment low. Overall, 70% of pregnant women received some form of antiretroviral prophylaxis, 64% of HIV exposed infants accessed early infant diagnosis by PCR around 6 weeks postpartum and 55% were tested between 12 and 18 months.

The risk of mother-to-child HIV transmission can be dramatically reduced by preventive measures including antiretroviral prophylaxis for the mother and the child [2]. According to a recent WHO update, the use of cART during pregnancy is preferable to mono- or dual therapy [4]. Our analysis showed that some women received sdNVP at their first visit and were then lost before dual or triple prophylaxis or cART could be initiated. In other cases it was unknown why the optimal regimen had not been provided even though it was available. Significantly, about one third of patients did not receive any type of antiretroviral prophylaxis, and 40% of cART eligible women did not initiate treatment. This finding is in line with recent systematic reviews on retention in HIV care, which reported that between 38% and 88% of pregnant women [30], and 32% and 37% of eligible patients from the general HIV infected population never started cART [31, 32]. An important difference between pregnant women and the general, HIV-infected population is that a substantially lower proportion of pregnant women were eligible for cART at first presentation (23% and 40% [31], respectively). This shows that with systematic HIV testing during pregnancy HIV infection can be diagnosed earlier, providing opportunities to initiate cART before patients present with advanced disease.

In a previous review Hensen et al [33] compared HIV-testing uptake before and after implementation of the opt-out strategy and found a substantial increase in uptake, from 10% to 66%. In our analysis, which included studies with either opt-in or opt-out testing, we found that the mean uptake was 94% with the opt-out strategy. The consistency of results across programs was striking and in contrast to the pronounced heterogeneity of results with the opt-in strategy. In general, pregnant women may be reluctant to be tested for many reasons, including structural and socio-cultural barriers [34, 35]. However, the provision of universal opt-out HIV-testing in antenatal care clinics might remove some of the fears related to patient-initiated testing, as it “normalizes” the testing process and integrates it into
routine clinical care. As a consequence, women might be less afraid of being stigmatized and judged by their peers. The studies included in this analysis showed enhanced uptake of testing if patients were accompanied by their male partner [20]. Finally, programmatic issues such as staff shortages or the unavailability of test kits might also limit HIV-testing uptake [36].

In our meta-analysis about two thirds of the HIV-exposed infants returned for EID and even less for HIV testing between 12 and 18 months postpartum. We analyzed coverage of HIV infant testing in programs where mothers were informed about the importance of testing their child. Preventing transmission from mothers who seroconvert while breastfeeding, or who are not attending an antenatal care clinic, is probably even more difficult than in women who attended an antenatal care clinic during pregnancy [37]. Several strategies aimed at increasing the uptake of infant testing have been evaluated [38]. For example, Rollins et al showed that universal HIV-testing of infants at immunization clinics was acceptable and feasible in rural South Africa, with 90% of women agreeing to have their infant tested [39]. WHO and most national guidelines recommend universal treatment of all HIV-infected children under two years of age. It is therefore important to develop effective strategies for testing children for HIV in infancy.

In order to increase the uptake of PMTCT interventions, our understanding of the individual and program-level factors that limit access to care must improve. Although few studies analyzed barriers to pre-ART care, integration of cART provision into routine antenatal services and reducing the number of visits seems promising. An example of this was the improved uptake of cART when the CD4 count was done on the same day as testing for HIV [8]. Better uptake was also associated with the provision of cART at the same place as PMTCT services [8, 21, 24], or if the distance to the clinic was short [8, 13]. In general, however, there is a lack of data on the effectiveness of integrating prevention of mother-to-child HIV transmission (PMTCT) programs with other health services. This is illustrated by a Cochrane review on this topic [40], which found only one study that matched the inclusion criteria. The involvement of the male partner may also increase the chance of successful interventions [20]. In a study from Côte d’Ivoire a family centered approach (i.e. provision of cART to partner and children; and improved access to contraception) helped to achieve coverage of over 90% from CD4 measurement to EID.

Our review provides a unique overview on the uptake of diagnostic and interventional steps throughout the PMTCT cascade in sub-Saharan Africa. The studies included in this review represent a wide range of urban, semi-urban and rural health care settings from many regions of sub-Saharan Africa. There are, however, several limitations: As noted previously, there were important differences between studies, which led to heterogenous results and wide prediction intervals. Furthermore, the studies were conducted over eight years, a period in which HIV testing, treatment and prevention strategies evolved substantially. For example, the studies evaluating opt-out HIV-testing were performed later than those with opt-in strategies, possibly leading to bias due to an increase in the level of HIV awareness and quality of care over time. Most of the studies did not trace patients lost to follow-up or assess predictors for losses to program. They could thus not contribute to a better understanding of the reasons for attrition. In the context of initiation of lifelong cART in eligible women, we did not consider different CD4 cell count thresholds for starting cART, and studies did not report whether eligibility was based on CD4 cell count or stage of disease. Finally, none of the studies evaluated the option B+ approach and only one study reported on cART initiation in HIV-infected infants.
Conclusion

In order to reach the UNAIDS goal of eliminating paediatric HIV infections by 2015 [41], the coverage of PMTCT and cART need to be improved. Even though provider-initiated HIV-testing shows promising results, large gaps in antiretroviral prophylaxis, cART initiation, and infant testing remain. In order to improve retention in care of HIV-infected mothers and prevent new HIV-infections in children, a better understanding of the major barriers is of paramount importance. Further research on the major reasons for the failure of PMTCT programs in sub-Saharan Africa is urgently needed.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Kali Tal for editorial help and Marcel Zwahlen for statistical support.

Sources of Funding:

The study was supported by the National Institute of Allergy and Infectious Diseases (NIAID), Grant 5U01-AI069924-05, a PROSPER fellowship grant to O.K., funded by the Swiss National Science Foundation (Grant 3233SB_131629) and PhD fellowships to J.E. and N.B. from the Swiss School of Public Health and the Swiss National Science Foundation.

References

5. WHO. Prevention of Mother-To-Child Transmission (PMTCT), Briefing Note. 2007.

AIDS. Author manuscript; available in PMC 2013 November 28.


31. Mugglin, CEJ.; Wandeler, G., et al. Linkage to Care from HIV Diagnosis to Start of ART in sub-Saharan Africa: Meta-analysis; 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012); Seattle, WA. 2012;


36. Doherty T, Chopra M, Nsibande D, Ngxonga D. Improving the coverage of the PMTCT programme through a participatory quality improvement intervention in South Africa. BMC Public Health. 2009; 9


AIDS. Author manuscript; available in PMC 2013 November 28.
Figure 1. Steps of the prevention of mother-to-child-transmission cascade
Bold arrows represent steps with risk of attrition
ANC=antenatal care, cART=lifelong combination ART, ARVs=antiretroviral drugs,
PCR=polymerase chain reaction

Included studies reporting about the individual steps
(i) HIV-testing
   27 studies
   [7, 13-18, 20, 21, 23, 24, 28, 36, 42-55]
(ii) ARV prophylaxis without prior cART eligibility assessment
    23 studies
    [7, 9-12, 14, 16, 17, 20, 23, 27, 42, 45, 46, 48-51, 53-57]
(iii) cART eligibility assessed
     14 studies
     [8, 13, 18, 19, 21, 22, 24, 28, 36, 47, 52, 58-60]
(iv) cART initiation
    12 studies
    [8, 13, 18, 21, 22, 24, 25, 28, 44, 52, 58, 59]
(v) HIV testing of exposed infants
   a) early infant diagnosis around 6 weeks: 13 studies
      [7, 11, 15, 19, 26-29, 36, 57, 59-61]
   b) testing at 12-18 months postpartum: 8 studies
      [7, 9, 16, 43, 51, 54, 59, 61]
(vi) Treatment initiation in HIV+ infants
    1 study
    [29]
Figure 2. Meta-analyses of uptake of HIV testing in pregnant women by testing strategy
Top panel: Uptake of opt-out HIV testing
Bottom panel: Uptake of opt-in HIV testing
Figure 3. Coverage with antiretroviral drugs for prevention of mother-to-child-transmission (PMTCT)
Estimates are pooled estimates from meta-analyses providing data on the whole time period of each graph.
HIV+ = HIV positive, cART = antiretroviral combination therapy
Figure 4.
Uptake of early infant diagnosis by polymerase chain reaction (PCR) around 6 weeks postpartum and infant testing between 12 and 18 months postpartum if the program did not provide early infant diagnosis by PCR or the child was HIV negative at PCR testing.
### Table 1

Characteristics of included studies

<table>
<thead>
<tr>
<th>Author (publication year)</th>
<th>Study-Period</th>
<th>No. HIV+ pregnant women incl in study</th>
<th>No. of HIV exposed newborns incl in study</th>
<th>Location (No. of sites, city or region, country)</th>
<th>Setting</th>
<th>Inclusion/exclusion criteria for participants</th>
<th>Eligibility for cART CD4 count (cells/mm³), WHO stage</th>
<th>PMTCT regimen (Pregnant women/exposed infant)</th>
<th>Age at Infant testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azcoaga-Lorenzo (2011)</td>
<td>2006-2008</td>
<td>1668</td>
<td>485</td>
<td>11 sites, Busia District, Kenya</td>
<td>n.r.</td>
<td>All pregnant women attending ANC</td>
<td>n.r.</td>
<td>cART, AZT+3TC+sdNVP/sdNVP+AZT</td>
<td>6 weeks, 6 weeks after weaning, 2nd test</td>
</tr>
<tr>
<td>Balcha (2011)</td>
<td>2007-2008</td>
<td>2232</td>
<td>2232</td>
<td>112 sites, Oromia region, Ethiopia</td>
<td>n.r.</td>
<td>All pregnant women attending ANC</td>
<td>n.r.</td>
<td>sdNVP/sdNVP</td>
<td>n.r.</td>
</tr>
<tr>
<td>Braun (2011)</td>
<td>2004-2008</td>
<td>14669</td>
<td>14669</td>
<td>6 sites, Lilongwe District, Malawi</td>
<td>Urban</td>
<td>All HIV-tested pregnant women attending ANC and infants born and tested since 2004</td>
<td>&lt;250 III+IV</td>
<td>cART, sdNVP/sdNVP</td>
<td>6 weeks, 6 weeks after weaning</td>
</tr>
<tr>
<td>Chama (2007)</td>
<td>2002-2004</td>
<td>92</td>
<td>52</td>
<td>1 site, Maiduguri, Nigeria</td>
<td>Urban</td>
<td>All pregnant women attending ANC</td>
<td>&lt;200 III+IV</td>
<td>cART, sdNVP/sdNVP</td>
<td>18 months</td>
</tr>
<tr>
<td>Chama (2010)</td>
<td>2007-2008</td>
<td>695</td>
<td>506</td>
<td>1 site, Maiduguri, Nigeria</td>
<td>Urban</td>
<td>All pregnant women attending ANC</td>
<td>&lt;200 III+IV</td>
<td>cART, AZT+3TC+IND/r, TDF+FTC+IND/r/sdNVP+AZT</td>
<td>6 and 13 weeks, every 3 month, last test 3 month after weaning</td>
</tr>
<tr>
<td>Chen (2010)</td>
<td>2007-2008</td>
<td>n.r.</td>
<td>793</td>
<td>1 site, Gaborone, Botswana</td>
<td>Urban</td>
<td>All pregnant women attending ANC and delivering within study period, &gt;20 weeks of gest age at delivery</td>
<td>&lt;200/250 IV</td>
<td>cART, AZT+sdNVP/n.r.</td>
<td>n.r.</td>
</tr>
<tr>
<td>Author (publication year)</td>
<td>Study-Period</td>
<td>No. HIV+ pregnant women incl in study</td>
<td>No. of HIV exposed newborns incl in study</td>
<td>Location (No. of sites, city or region, country)</td>
<td>Setting</td>
<td>Inclusion/exclusion criteria for participants</td>
<td>Eligibility for cART CD4 count (cells/mm³), WHO stage</td>
<td>PMTCT regimen (Pregnant women/exposed infant)</td>
<td>Age at Infant testing</td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------------</td>
<td>--------------------------------------</td>
<td>------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>---------</td>
<td>------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>----------------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Ciampa (2011)</td>
<td>2009-2010</td>
<td>395</td>
<td>395</td>
<td>2 sites, Alto molócué andNamacurra, Zambézia Province, Mozambique</td>
<td>Rural</td>
<td>All HIV+ pregnant women who gave birth at study hospital</td>
<td>≤350 III+IV</td>
<td>cART, AZT+3TC/ sdNVP, AZT</td>
<td>4 weeks</td>
</tr>
<tr>
<td>Colvin (2007)</td>
<td>2002-2004</td>
<td>665</td>
<td>665</td>
<td>3 sites, Paarl, Rietvlei, Umlazi, South Africa</td>
<td>Rural, semi-urban</td>
<td>All HIV+ pregnant women and their infants attending ANC at 3 of the 18 national PMTCT pilot sites</td>
<td>n.r.</td>
<td>sdNVP/sdNVP</td>
<td>3-4 weeks</td>
</tr>
<tr>
<td>Cook (2011)</td>
<td>2007-2008</td>
<td>450</td>
<td>450</td>
<td>1 site, Alto molócué, Mozambique</td>
<td>Rural</td>
<td>All HIV+ pregnant women attending ANC, mother infant pairs were excluded if infant was ineligible for DBS PCR at postnatal follow-up (&lt;1mth or &gt;18mth)</td>
<td>n.r.</td>
<td>cART, AZT+sdNVP, sdNVP/sdNVP+AZT, sdNVP</td>
<td>1-18 months</td>
</tr>
<tr>
<td>Creek (2007)</td>
<td>2003-2004</td>
<td>345</td>
<td>n.r.</td>
<td>4 sites, Francistown, Botswana</td>
<td>Urban</td>
<td>All pregnant women attending ANC</td>
<td>n.r.</td>
<td>AZT/n.r.</td>
<td>n.r.</td>
</tr>
<tr>
<td>Doherty (2009)</td>
<td>2007</td>
<td>3071</td>
<td>3071</td>
<td>21 sites, Abajuba District, South Africa</td>
<td>n.r.</td>
<td>All pregnant women attending ANC</td>
<td>n.r.</td>
<td>sdNVP /sdNVP</td>
<td>n.r.</td>
</tr>
<tr>
<td>Ekomouvi (2004)</td>
<td>2002</td>
<td>226</td>
<td>n.r.</td>
<td>5 sites, Abidjan, Côte d’Ivoire</td>
<td>Urban</td>
<td>All pregnant women attending ANC</td>
<td>n.r.</td>
<td>AZT+sdNVP/n.r.</td>
<td>n.r.</td>
</tr>
<tr>
<td>Geddes (2011)</td>
<td>2004-2007</td>
<td>703</td>
<td>699</td>
<td>1 site, Durban, South Africa</td>
<td>Urban</td>
<td>All pregnant women attending ANC</td>
<td>&lt;200</td>
<td>cART, AZT+sdNVP, tripleARV*/ sdNVP+AZT, sdNVP</td>
<td>6 weeks</td>
</tr>
<tr>
<td>Homsey (2006)</td>
<td>2004-2005</td>
<td>278</td>
<td>n.r.</td>
<td>1 site, Tororo, Uganda</td>
<td>Rural</td>
<td>All pregnant women attending ANC</td>
<td>n.r.</td>
<td>sdNVP/sdNVP</td>
<td>n.r.</td>
</tr>
<tr>
<td>Kasenga (2009)</td>
<td>2005-2007</td>
<td>635</td>
<td>n.r.</td>
<td>1 site, Makwasa, Malawi</td>
<td>Rural</td>
<td>All pregnant women attending ANC</td>
<td>n.r.</td>
<td>sdNVP/sdNVP</td>
<td>n.r.</td>
</tr>
<tr>
<td>Kiptoo (2009)</td>
<td>2005-2006</td>
<td>309</td>
<td>n.r.</td>
<td>3 sites, Kitale, Kapsabet, Nandi Hills, Kenya</td>
<td>Rural</td>
<td>All pregnant women attending ANC for the 1st time during current pregnancy</td>
<td>&lt;200</td>
<td>ARV*/n.r.</td>
<td>n.r.</td>
</tr>
<tr>
<td>Kirere (2008)</td>
<td>2002-2004</td>
<td>94</td>
<td>101</td>
<td>1 site, Oicha, Democratic Republic of Congo</td>
<td>Rural</td>
<td>All pregnant women attending ANC with gest age &gt; 36weeks</td>
<td>n.r.</td>
<td>sdNVP/sdNVP</td>
<td>n.r.</td>
</tr>
<tr>
<td>Kouam (2006)</td>
<td>2003-2004</td>
<td>22</td>
<td>18</td>
<td>1 sites, Yaoundé, Cameroon</td>
<td>Urban</td>
<td>All pregnant women attending ANC</td>
<td>n.r.</td>
<td>sdNVP/sdNVP</td>
<td>6 weeks, 6 and 15-18</td>
</tr>
<tr>
<td>Author (publication year)</td>
<td>Study Period</td>
<td>No. HIV+ pregnant women incl in study</td>
<td>No. of HIV exposed newborns incl in study</td>
<td>Location (No. of sites, city or region, country)</td>
<td>Setting</td>
<td>Inclusion/exclusion criteria for participants</td>
<td>Eligibility for cART (CD4 count (cells/mm3), WHO stage)</td>
<td>PMTCT regimen (Pregnant women/exposed infant)</td>
<td>Age at Infant testing</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------------</td>
<td>--------------------------------------</td>
<td>------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>---------</td>
<td>-------------------------------------------</td>
<td>------------------------------------------------</td>
<td>-------------------------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Kumwenda (2011)</td>
<td>2004-2009</td>
<td>3335</td>
<td>n.r.</td>
<td>6 sites, Blantyre, Malawi</td>
<td>Urban</td>
<td>All HIV+ pregnant women attending ANC or giving birth at study site, willing to return for postnatal follow-up and breastfeed the infant</td>
<td>cART, &lt;250</td>
<td>cART, sdNVP/sdNVP+AZT</td>
<td>n.r.</td>
</tr>
<tr>
<td>Mandala (2009)</td>
<td>2007-2008</td>
<td>14815</td>
<td>n.r.</td>
<td>60 sites, Northern, Luapula, Copperbelt, Central, North Western Province, Zambia</td>
<td>Rural</td>
<td>All HIV+ pregnant women attending ANC</td>
<td>cART, ARV*, sdNVP/ARV*</td>
<td>n.r.</td>
<td></td>
</tr>
<tr>
<td>Manzi (2005)</td>
<td>2002-2003</td>
<td>646</td>
<td>206</td>
<td>69 sites, Thylo District, Malawi</td>
<td>Rural</td>
<td>All pregnant women attending ANC</td>
<td>n.r.</td>
<td>sdNVP/sdNVP</td>
<td>18 months</td>
</tr>
<tr>
<td>Marazzi (2010)</td>
<td>2005-2009</td>
<td>3273</td>
<td>31-48</td>
<td>19 DREAM centers and 4 laboratories, Malawi and Mozambique</td>
<td>n.r.</td>
<td>All HIV+ pregnant women attending ANC, availability on data on pregnancy outcome, intent to follow-up in program, willing to breastfeed</td>
<td>cART, &lt;350</td>
<td>cART, tripleARV+/n.r.</td>
<td>4 weeks, 6 and 12 months</td>
</tr>
<tr>
<td>Mirkuzie (2011)</td>
<td>2009</td>
<td>282</td>
<td>221</td>
<td>15 sites, Addis Ababa, Ethiopia</td>
<td>Urban</td>
<td>All HIV+ pregnant women attending ANC and infant ≥6 weeks of age at closure of study</td>
<td>cART, AZT+3TC+sdNVP/sdNVP+AZT</td>
<td>n.r.</td>
<td>6 weeks</td>
</tr>
<tr>
<td>Moodley (2011)</td>
<td>2007</td>
<td>258</td>
<td>n.r.</td>
<td>2 sites, Umlazi catchment area, Kwala-Zulu-Natal, South Africa</td>
<td>Semi-urban, urban</td>
<td>All women presenting at postnatal ward within 48h of delivery</td>
<td>cART, sdNVP/sdNVP</td>
<td>n.r.</td>
<td></td>
</tr>
<tr>
<td>Msuya (2006)</td>
<td>2002-2004</td>
<td>184</td>
<td>n.r.</td>
<td>2 sites, Majengo and Passa, Tanzania</td>
<td>Urban</td>
<td>All pregnant women attending ANC, were pregnant in 3rd trimester, resident of Moshi urban district</td>
<td>n.r.</td>
<td>sdNVP/sdNVP</td>
<td>n.r</td>
</tr>
<tr>
<td>Namukwaya (2011)</td>
<td>2007-2009</td>
<td>7941</td>
<td>4807</td>
<td>1 site, Kampala, Uganda</td>
<td>Urban</td>
<td>All HIV+ pregnant women attending ANC</td>
<td>cART, AZT+3TC+sdNVP, AZT+sdNVP/sdNVP+AZT</td>
<td>n.r.</td>
<td>6 weeks</td>
</tr>
<tr>
<td>Author (publication year)</td>
<td>Study-Period</td>
<td>No. HIV+ pregnant women incl in study</td>
<td>No. of HIV exposed newborns incl in study</td>
<td>Location (No. of sites, city or region, country)</td>
<td>Setting</td>
<td>Inclusion/exclusion criteria for participants</td>
<td>Eligibility for cART CD4 count (cells/mm3), WHO stage</td>
<td>PMTCT regimen (Pregnant women/exposed infant)</td>
<td>Age at Infant testing</td>
</tr>
<tr>
<td>--------------------------</td>
<td>--------------</td>
<td>--------------------------------------</td>
<td>------------------------------------------</td>
<td>---------------------------------</td>
<td>---------</td>
<td>--------------------------------------</td>
<td>----------------------------------</td>
<td>---------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Oladokun (2010)</td>
<td>2002-2007</td>
<td>2157</td>
<td>303</td>
<td>1 site, Ibanan, Nigeria</td>
<td>Urban</td>
<td>All pregnant women attending ANC, babies born until end of 2005</td>
<td>n.r.</td>
<td>ARV*/n.r.</td>
<td>18 months</td>
</tr>
<tr>
<td>Orie (2009)</td>
<td>2007</td>
<td>227</td>
<td>227</td>
<td>1 site, Pietermaritzburg, South Africa</td>
<td>Urban</td>
<td>All pregnant women attending ANC and delivering at regional hospital, women who did not attend ANC at hospital were excluded</td>
<td>&lt;200 IV</td>
<td>cART, sdNVP/sdNVP</td>
<td>n.r.</td>
</tr>
<tr>
<td>Peltzer (2008)</td>
<td>2005-2006</td>
<td>116</td>
<td>116</td>
<td>5 sites, Quakeni Area, South Africa</td>
<td>Rural</td>
<td>All pregnant women with confirmed HIV status, women with unknown HIV status were excluded</td>
<td>n.r.</td>
<td>sdNVP/sdNVP</td>
<td>9 months</td>
</tr>
<tr>
<td>Rutta (2008)</td>
<td>2002-2007</td>
<td>301</td>
<td>184</td>
<td>6 sites, Greater Lukole camp, Nagara District, Tanzania</td>
<td>Rural</td>
<td>All pregnant women attending ANC</td>
<td>n.r.</td>
<td>sdNVP/sdNVP</td>
<td>18 months</td>
</tr>
<tr>
<td>Stinson (2010)</td>
<td>2005</td>
<td>3498</td>
<td>380</td>
<td>4 sites, Cape Town, South Africa</td>
<td>Urban</td>
<td>All pregnant women attending ANC</td>
<td>&lt;200 IV</td>
<td>cART, AZT+sdNVP, sdNVP/sdNVP</td>
<td>n.r.</td>
</tr>
<tr>
<td>Stringer (2005)</td>
<td>2003</td>
<td>1140</td>
<td>1140</td>
<td>25 sites, Lusaka, Zambia</td>
<td>Urban</td>
<td>All pregnant women attending ANC, mother with delivery before arrival at clinic were excluded</td>
<td>n.r.</td>
<td>sdNVP/sdNVP</td>
<td>n.r.</td>
</tr>
<tr>
<td>Teijokem (2011)</td>
<td>2007-2009</td>
<td>1587</td>
<td>1587</td>
<td>3 sites, Douala and Yaounde, Cameroon</td>
<td>Urban</td>
<td>All life-born infants to HIV+ mothers who enrolled in the 1st phase of the PEDICAM study, random exclusion of 1 of the infants in cases of twins</td>
<td>n.r.</td>
<td>ARV*/n.r.</td>
<td>6 weeks</td>
</tr>
<tr>
<td>Towne-Gold (2007)</td>
<td>2003-2005</td>
<td>261</td>
<td>231</td>
<td>2 sites, Abidjan, Cote d’Ivoire</td>
<td>Urban</td>
<td>All pregnant women enrolled in the MTCT plus Initiative</td>
<td>&lt;200 IV</td>
<td>cART, AZT+3TC+sdNVP, sdNVP/sdNVP+AZT</td>
<td>4 weeks, 12 months</td>
</tr>
<tr>
<td>Author</td>
<td>Study-Period</td>
<td>No. HIV+ pregnant women incl in study</td>
<td>No. of HIV exposed newborns incl in study</td>
<td>Location (No. of sites, city or region, country)</td>
<td>Setting</td>
<td>Inclusion/exclusion criteria for participants</td>
<td>Eligibility for cART CD4 count (cells/mm³), WHO stage</td>
<td>PMTCT regimen (Pregnant women/exposed infant)</td>
<td>Age at Infant testing</td>
</tr>
<tr>
<td>------------------------</td>
<td>--------------</td>
<td>--------------------------------------</td>
<td>-------------------------------------------</td>
<td>-------------------------------------------------</td>
<td>---------</td>
<td>-----------------------------------------------</td>
<td>---------------------------------------------------</td>
<td>-------------------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Tsague (2010)</td>
<td>2006-2008</td>
<td>2048</td>
<td>n.r.</td>
<td>32 sites, Kibuye Region, Gisenyi Region and Kigali, Rwanda</td>
<td>n.r.</td>
<td>All pregnant women attending ANC</td>
<td>&lt;350 IV</td>
<td>cART, scAZT+3TC+sdNVP/sdNVP+AZT</td>
<td>n.r.</td>
</tr>
<tr>
<td>Tukur (2007)</td>
<td>2003-2005</td>
<td>125</td>
<td>n.r.</td>
<td>1 site, Kano, Nigeria</td>
<td>Urban</td>
<td>All HIV+ pregnant women delivering at study hospital</td>
<td>n.r.</td>
<td>cART, triple ARV, sdNVP/sdNVP</td>
<td>3 days</td>
</tr>
<tr>
<td>Van der Merwe (2006)</td>
<td>2004-2005</td>
<td>1027</td>
<td>1027</td>
<td>1 site, Johannesburg, South Africa</td>
<td>Urban</td>
<td>All HIV+ pregnant women attending ANC</td>
<td>&lt;250 IV</td>
<td>cART, sdNVP/sdNVP</td>
<td>6 weeks</td>
</tr>
<tr>
<td>Wanyu (2007)</td>
<td>2002-2005</td>
<td>82</td>
<td>64</td>
<td>20 sites, Cameroon</td>
<td>Rural</td>
<td>All pregnant women counseled by traditional birth attendant</td>
<td>n.r.</td>
<td>sdNVP/sdNVP</td>
<td>15 months</td>
</tr>
</tbody>
</table>

cART = lifelong antiretroviral therapy, sdNVP = single dose nevirapine at birth, AZT = zidovudin, 3TC = lamivudin, IND/r = ritonavir boosted indinavir, TDF = tenofovir, FTC = emtricitabin, ANC = antenatal care, HIV+ = HIV positive, incl = included, n.r. = not reported, MTCT = mother-to-child-transmission

*ARV = antiretroviral prophylaxis, regimen not specified, tripleARV*=triple prophylaxis including different regimens